Title: Medical Innovation Act of 2017
Author: Sen. Elizabeth Warren (DEM-MA)
Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally funded research.</p> <p>Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.</p> <p>Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.</p> ...
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
12/04/2017 - S 2172 (Introduced+in+Senate)
11/29/2017 - S 2172 (Introduced+in+Senate)
Add To Favorites In PHR
Sen. Elizabeth Warren (D-MA)
() - U.S. Senate
Visit their Website
317 Hart Senate Office Building
Washington, DC 20510
Phone: (202) 224-4543
2400 JFK Federal Building, 15 New Sudbury Street
Phone: (617) 565-3170